DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its… Sep 20, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 Sep 13, 2021
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative… Aug 25, 2021
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida Aug 24, 2021
Cybin Strengthens IP Portfolio By Filing Of 16th Patent Application: Psychedelic Investors React Aug 20, 2021
